The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains:
N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C
wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 includes an amino acid sequence represented by GFTFSNY (SEQ ID NO: 1); the CDR2 includes an amino acid sequence represented by NSGGTG (SEQ ID NO: 2); and the CDR3 includes an amino acid sequence represented by RVDGRVLSTIVVSYDY (SEQ ID NO: 3). The antibody is capable of binding to an intranuclear protein of an influenza virus.

A lateral flow assay cassette comprising a swab holder is provided herein. Also provided are kits comprising the lateral flow assay cassette and methods of detecting an analyte.

The present disclosure relates to a system for viral monitoring in effluent, comprising a biosensor including a graphene-based field-effect transistor having capture proteins conjugated thereto, the capture proteins being configured to bind a virus, and a fluidic channel arranged above the graphene-based field-effect transistor so that fluid of the effluent flows over the graphene-based field-effect transistor, and processing circuitry configured to apply a gate voltage to the graphene-based field-effect transistor, measure a conductance across the graphene-based field-effect transistor, the conductance reflecting an amount of the virus bound to the capture proteins, compare the measured conductance to a threshold conductance, and transmit, to a computing device and when the comparison indicates the measured conductance satisfies the threshold conductance, information indicating a presence of the virus in the effluent. In certain embodiments, the capture proteins may be SARS-CoV-2 spike antibodies.

A system for viral monitoring in effluent includes at least one graphene-based field-effect transistor and circuitry, wherein the circuitry is configured to repeatedly monitor and determine presence of SARS-CoV-2 (COVID virus) in the effluent. The circuitry is configured to apply a gate voltage and measure a conductance across each of the at least one graphene-based field-effect transistor, compare the measured conductance across each of the at least one graphene-based field-effect transistor to a threshold conductance, and determine whether levels of the COVID virus exceed a predetermined threshold in the effluent. If levels of the COVID virus exceed the predetermined threshold in the effluent, the circuitry is configured to remove at least a portion of the bound COVID virus from the proteins of the at least one graphene-based field-effect transistor.

The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

Provided herein are methods of detecting Ebola virus in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first or second epitopes of glycoproteins, such as secreted glycoproteins (sGPs) from the Ebola virus under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first or second epitopes of the glycoproteins from the Ebola virus in the sample to produce bound glycoproteins. The methods also include detecting the glycoproteins from the Ebola virus when aggregations of the bound glycoproteins form with one another. Related reaction mixtures, devices, kits, and systems are also provided.

A sensor for detecting a target pathogen (e.g., a virus or a bacterium) in a specimen is disclosed, which includes at least two sensing units one of which is configured to detect at least one protein (such as a structural protein) associated with the target pathogen and another one is configured to detect at least one genetic component (e.g., an RNA or a DNA segment) associated with that pathogen (e.g., an RNA segment that is unique to that pathogen).

A method for detecting MERS-CoV at high sensitivity and specificity using IgY antibodies that bind to MERS-CoV N protein, its fragments and domains. Isolated or purified IgY monospecific antibodies to MERS-CoV N protein.

An article of manufacture comprises an optical shade configured for removable attachment to eyewear, e.g., eyeglasses that are retrofitted to include a micro-fluidic tear collector in a nose pad. The optical shade comprises a lens having a lateral flow assay comprising an antibody having an associated fluorescent tag. The fluorescent tag is configured to fluoresce and change a color of the lens upon detection by the flow assay of an antigen that matches the antibody. The antigen comprises viral constituents, such as SARS-CoV-2. The color change of the lens is visible and indicates presence of Covid-19 infection.

The invention provides compositions and methods for inhibiting the interaction of the SARS-CoV-2 S protein and one or more SARS-CoV-2 S protein interacting protein, and methods of use thereof.